Abstract
To confirm the efficacy and safety of bevacizumab/XELOX combination for the treatment of locally advanced or metastatic colorectal cancer (CRC) in Italy.
Leibniz-HKI-Authors
Identifier
doi: 10.3748/wjg.v21.i23.7281
PMID: 26109816
To confirm the efficacy and safety of bevacizumab/XELOX combination for the treatment of locally advanced or metastatic colorectal cancer (CRC) in Italy.
doi: 10.3748/wjg.v21.i23.7281
PMID: 26109816